Erica Slaughter

A new report shows that multiple sclerosis diagnoses have steadily risen in older patients in the past 5 years, bucking previous patient rate estimates.

The known medium of communication between the immune system and central nervous system, metabolites could believably play a role in the multiple sclerosis disease course.

Early findings indicate that Sephin1 could lead to better clinical outcomes in MS patients as a safe, neuroprotective drug.

The 1100-patient study is comparing once-daily ponesimod and teriflunomide for patients with the relapsing form of the disease.

With a recent FDA approval as the first ever therapy for TD, as well as the first ongoing phase 4 clinical trial, valbenazine use is under close watch by clinicians and specialists.

Active-duty military personnel report a deadly opioid overdose rate just one-fourth of the general population. What does the military do with its patient registries that could be repeatable in public health?

In response to the evidenced connection between pediatric asthma development and air pollution exposure, investigators have sought out association indicators as early as in utero.

The UCSF group of Vikram Rao, MD, PhD; Paul Garcia, MD; Edward Chang, MD; and Robert Knowlton, MD, have found a means to achieve seizure remission—and even predict future seizure activity.

A growing class of medications, SGLT-2 inhibitors have helped physicians manage otherwise uncontrolled cases of type 2 diabetes.

Relying on qEEG to map the grid of brain waves, physicians can use neurofeedback therapy to train themselves to improve behavioral outcomes, such as sharper focus and reduced distractibility.